Celtic Pharmaceutical Holdings L.P.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celtic Pharmaceutical Holdings L.P.
Japanese bioventure Stella Pharma is re-designing a Phase II trial for its glioma candidate Steboronine after it was determined the original primary endpoint was not robust enough to prove efficacy, a challenge faced by some others working in the difficult indication. The drug was approved for head and neck cancer in Japan in 2020 and Stella has already announced a new collaboration which may be key to moving forward.
Deal Snapshot: In its third biopharma collaboration this year, Ginkgo will apply its genetic engineering technologies to using Bacteroides for stable delivery of microbiome medicines.
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
- Other Names / Subsidiaries
- Auven Therapeutics Management L.L.L.P.
- Celtic Pharma Management
- Xenova Limited
- Celtic Therapeutics Holdings L.P.